Hypersomatostatinemia in chronic renal failure.
Plasma concentrations of somatostatin-like immunoreactivity (SLI) were determined in uremic patients on maintenance hemodialysis. Plasma SLI levels were significantly (p less than 0.001) elevated in 26 diabetic uremic patients (67.1 +/- 6.8 pg/ml, mean +/- SE) and in 24 non-diabetic uremic patients (43.5 +/- 7.2 pg/ml), when compared with 60 healthy subjects (5.0 +/- 0.7 pg/ml). Paired pooled plasma from uremic patients before and after hemodialysis was subjected to a reverse-phase octadecasilyl-silica (C-18) cartridge and then the extract was gel filtered on a Sephadex G-25 column (1.6 X 90 cm). Both elution profiles showed two peaks of SLI which coeluted with synthetic somatostatin (SS)-28 and SS-14 markers, respectively. The SS-28-like immunoreactivity (LI) peak, which was estimated by using SS-14 as a reference standard, was 3-fold larger than that for SS-14 LI. On the basis of immunoequivalency of the two components in the present assay, SS-28 LI constitutes approximately 75% of circulating somatostatin. In conclusion, plasma SLI is substantially high in uremic patients of both diabetic and non-diabetic etiology and the SS-28 is a predominant form of circulating SLI in these patients, probably, in part, for a lower clearance of this molecule.
D002850:Chromatography, Gel; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood*; D008875:Middle Aged; D010455:Peptides / Q000097:blood*; D011863:Radioimmunoassay; D006435:Renal Dialysis; D013004:Somatostatin / Q000097:blood; D053561:Somatostatin-28; D014511:Uremia / Q000150:complications
D010455:Peptides; C029993:somatostatin-like peptides; D013004:Somatostatin; D053561:Somatostatin-28